Halyard Health (NYSE:HYH) said late last month it tapped former Acelity prez & CEO Joseph Woody as its new chief executive officer, replacing a retiring Robert Abernathy.
Woody will also assume a seat on the board of directors, with former CEO Abernathy continuing on as board chair, the Alpharetta, Ga.-based company said.
“On behalf of the board and Halyard employees, we are grateful for Robert’s dedicated leadership these past three plus years. During his tenure, Robert re-established Halyard’s innovative culture and positioned the company for future growth. Halyard is successfully executing its transformation and we’re confident that we’ll continue to do so under Joe’s leadership. Joe is an experienced healthcare CEO with proven success driving revenue growth and spearheading portfolio transformations. He brings the laser focus needed to propel Halyard forward in this fast-paced industry. We’re pleased the board identified Joe to succeed Robert. We’re excited Joe is joining us and we’re fully optimistic about the future of Halyard,” independent lead director Ronald Dollens said in a prepared statement.
“Leading Halyard has been an incredible journey. I’m honored to have been part of this extraordinary team and thank everyone for their commitment to Halyard. Together, we’ve accelerated growth in our medical devices business, generated greater than expected free cash flow, and met or exceeded earnings analysts’ expectations the past seven quarters,” Abernathy said in a press release.
Woody served as Acelity’s CEO from 2011 until this April, stepping away following the company’s divestiture of its LifeCell division earlier this year.
“I’m thrilled to be joining Halyard. This talented team is poised to capitalize on the incredible opportunities that lie before us. We will continue to accelerate the execution of our transformation strategy,” Woody said in prepared remarks.
Conventus Orthopaedics said last week it tapped former Johnson & Johnson (NYSE:JNJ) DePuy Synthes executive Matthew Jewett as its new chief executive officer.
Prior to joining Conventus, Jewett held multiple executive leadership positions within the DePuy Synthes business, Minneapolis, Minn.-based Conventus Orthopaedics said.
“Matt’s strategic acumen and proven track record of leadership within orthopaedics made him the ideal choice to lead Conventus. We are pleased to have Matt join our company as we work to establish the Cage technology as the standard-of-care for the treatment of extremity fractures,” board chair Scott Flora said in a prepared statement.
Jewett joins Conventus following a successful career at Johnson & Johnson where he held multiple executive leadership positions within the DePuy Synthes business.
“I’m excited for the opportunity to lead Conventus, a company with a truly innovative technology for the treatment of extremity fractures. The Cage technology has the potential to both positively impact patient treatment outcomes as well as reduce the cost of care for extremity fracture treatment,” Jewett said in a press release.
Solos Endoscopy said on Sunday it appointed Dom Gatto as its new CEO and board chair, signing a 5-year employment agreement.
Prior to joining Solos, Gatto helped found medical device consulting firm AMG Development, and MedTrek, a surgical company which partnered with Olympus (TYO:7733). Gatto has also served as COO of start-up Acueity Healthcare.
“I look forward to the opportunity to bring Solos back to its prominent status within the medical device marketplace. As one of the pioneering endoscopic companies, its roots reach back to the beginning of the commercialization of endoscopic systems and tools. And we will look to capitalize on this rich history as we reposition the company for growth,” Gatto said in a press release.
Nevro Corp. (NYSE:NVRO) said today that its sales VP Michael Enxing has left the company.
Enxing joined the Redwood City, Calif.-based company in 2012. Prior to his time at Nevro, Enxing served as VP of Vertos Medical and has held multiple executive positions at Cardiovascular Systems (NSDQ:CSII), Advanced Neuromodulation Systems, Stryker (NYSE:SYK) and Tecnol Medical Products, according to Nevro’s website.
The company did not mention any details of Enxing’s exit in its press release announcement.
Acelity said late last month that Ramesh Subrahmanian will join the company as its new international region president, effective July 17.
Subrahanian previously served as group prez of Stryker (NYSE:SYK), responsible for commercial markets outside the US. He also served as Asia Pacific prez for Merck & Co, as well as a handful of commercial leadership roles at Sanofi, Acelity said.
“Markets across Asia Pacific, Europe and The Middle East represent tremendous potential not only to expand and grow our business, but to deliver our products and therapies to millions of patients in these areas who would benefit from our portfolio of healing solutions. Ramesh brings to Acelity a diverse and wide-ranging set of capabilities that will accelerate our global expansion plans. Together with John’s leadership in Europe, we are now well positioned to execute on our strategy of geographic expansion and truly deliver our therapies to people across the globe,” prez & CEO R. Eckert said in a press release.
The company said it also recently appointed John McAuley as European senior VP.
- IsoRay principal finance & accounting officer Branson departs
- Raumedic taps Kernan as CFO
- Visioneering Tech names Rapoport as CFO
- Lumicell appoints Geissler as chief medical officer
- Visioneering Tech adds to regional sales team
The post Halyard Health taps former Acelity head Woody for CEO | Personnel Moves July 5, 2017 appeared first on MassDevice.
from MassDevice http://ift.tt/2tRt6Jo
Cap comentari:
Publica un comentari a l'entrada